A Comparative Review of mRNA, Viral Vector, Inactivated, and Protein Subunit COVID-19 Vaccines
Main Article Content
Abstract
The COVID-19 pandemic prompted an unprecedented global response in vaccine development. Multiple platforms, including mRNA,
viral vector, inactivated, and protein subunit vaccines, were rapidly developed to curb the spread of SARS-CoV-2. This review provides a comparative analysis of these vaccine types, focusing on their mechanisms of action, efficacy, safety profiles, storage requirements, and global distribution. mRNA vaccines such as PfizerBioN Tech and Modern a demonstrated high efficacy, while viral vector vaccines like AstraZeneca and Johnson & Johnson offered logistical advantages. Inactivated vaccines such as Covaxin and Sinopharm are based on traditional methods and showed good safety profiles. Protein subunit vaccines like Novavax are emerging as a promising alternative with minimal side effects. Understanding these differences is essential for informed public health decisions, vaccine acceptance, and future pandemic preparedness.
References
Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med. 2020;383(27):2603–2615.
Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403–416.
Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomized controlled trials. Lancet. 2021;397(10269):99–111.
Sadoff J, Gray G, Vandebosch A, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N Engl J Med. 2021;384(23):2187–2201.
Ella R, Vadrevu KM, Jogdand H, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 3 trial. Lancet. 2021;398(10317):2173–2184.
Heath PT, Galiza EP, Baxter DN, et al. Safety and efficacy of NVX-CoV2373 COVID-19 vaccine. N Engl J Med. 2021;385(13):1172–1183.
World Health Organization (WHO). COVID-19 vaccine tracker and landscape. https://www.who.int/ (Accessed March 2025).
Krammer F. SARS-CoV-2 vaccines in development. Nature. 2020;586(7830):516–527.
Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines —a new era in vaccinology. Nat Rev Drug Discov. 2018;17(4):261–279.
Chen WH, Strych U, Hotez PJ, Bottazzi ME. The SARS-CoV-2 vaccine pipeline: an overview. Curr Trop Med Rep. 2020;7(2):61–64.
Ritter, J. M., Flower, R.J., Henderson, G., Loke, Y. K., MacEwan, D., Robinson, E. S. J.,& Fullerton, J. (2023). Rang & Dale,s Pharmacology (10thedition). Elsevier.
“Lippincott Illustrated Reviews: Pharmacology, Second South Asian Edition” by Sangeeta Sharma, Dinesh K Badyal, and Karen Whalen. 2023: 1003 –1007.
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.